盘龙药业：氟比洛芬贴剂开展临床试验获同意

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of the drug Fluorobufen patch, which is designed for pain relief and anti-inflammatory treatment in various conditions [1] Group 1: Product Details - The Fluorobufen patch was developed by Taisho Pharmaceutical Co., Ltd. and was first approved for sale in Japan on July 23, 1998 [1] - Indications for the product include osteoarthritis, periarthritis of the shoulder, tendinitis, tenosynovitis, lateral epicondylitis (such as tennis elbow), muscle pain, and swelling and pain after injury [1] - The product is classified as a Class 3 chemical drug and has not yet been launched in the domestic market [1] Group 2: Product Features - The patch features a controlled-release membrane design, which allows for a large drug load, low irritation, and a reduced likelihood of causing skin allergies [1] - It is particularly suitable for chronic pain conditions and scenarios where there is a higher demand for the patch's elasticity and adhesion [1]